RNA science has changed what medicine can do for patients. It’s as if we've learned a new language for writing medicines - and we are still early in that story.

@SailBiomeds is writing the next chapter. Their In Vivo CAR-T program uses eRNA™ and targeted nanoparticle delivery to instruct the immune system from within, with the goal of achieving durable remission for the hundreds of millions of patients with immune-mediated diseases.

Not managing these diseases, but ending them.

Today's announcement of a strategic partnership with @JNJInnovation is a meaningful step toward bringing this curative potential to patients in need.

Congratulations to the Sail and Flagship teams.

Flagship Pioneering (@FlagshipPioneer).#FlagshipFounded @SailBiomeds announced today a collaboration and option agreement with @JNJInnovation to advance it’s In Vivo CAR-T platform for immune-mediated diseases.

This milestone reflects years of pioneering work across the Flagship ecosystem—from foundational innovations in eRNA and targeted nanoparticle delivery to the creation of a platform with the potential to unlock an entirely new generation of programmable medicines.

Read the full announcement: flagshippioneering.com/news/…